Cargando…
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
There are few effective therapies for small cell lung cancer (SCLC), a highly aggressive disease representing 15% of total lung cancers. With median survival <2 years, SCLC is one of the most lethal cancers. At present, chemotherapies and radiation therapy are commonly used for SCLC management. F...
Autores principales: | Deneka, Alexander Y., Boumber, Yanis, Beck, Tim, Golemis, Erica A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769513/ https://www.ncbi.nlm.nih.gov/pubmed/31484422 http://dx.doi.org/10.3390/cancers11091297 |
Ejemplares similares
-
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
por: Khaddour, Karam, et al.
Publicado: (2021) -
An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion
por: Beck, Tim N., et al.
Publicado: (2019) -
Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression
por: Kharin, Leonid, et al.
Publicado: (2021) -
Case report: reinitiating pembrolizumab treatment after small bowel perforation
por: Beck, Tim N., et al.
Publicado: (2019) -
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model
por: Deneka, Alexander Y., et al.
Publicado: (2017)